Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,765 articles
📰
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she...
📰
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
📰
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she...
📰
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical...
📰
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
New data show brain-volume preservation correlates with patient outcomes
📰
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing...
📰
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial...
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell
• Avalo Therapeutics (NASDAQ:AVTX) is likely to report earnings for its fourth quarter.
• Idaho Strategic...
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell
• Avalo Therapeutics (NASDAQ:AVTX) is likely to report earnings for its fourth quarter.
• Idaho Strategic...
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell
• Avalo Therapeutics (NASDAQ:AVTX) is likely to report earnings for its fourth quarter.
• Idaho Strategic...
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell
• Avalo Therapeutics (NASDAQ:AVTX) is likely to report earnings for its fourth quarter.
• Idaho Strategic...
📰
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.
📰
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.
📰
Active ETFs Surge Past Passive, and These Are in the Lead
Actively managed ETFs have become increasingly popular among investors willing to pay a premium for flexibility, star managers, and sophisticated...
📰
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene...
📰
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting - marketscreener.com
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting marketscreener.com
Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases
SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Kali Therapeutics, a biotechnology company focused on the discovery and development of...
AbbVie Inc. $ABBV Stake Reduced by Gradient Investments LLC
Gradient Investments LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.4% in the fourth quarter, according to its most...
AbbVie Inc. $ABBV Stake Reduced by Gradient Investments LLC
Gradient Investments LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.4% in the fourth quarter, according to its most...
📰
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies (OTC:BSEM), a leading MedTech company focused on the development,...
📰
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative...
📰
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully...
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -
- GLIX1 is positioned to...
📰
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of...
📰
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product --
-- Third Commercial Site Transfer Agreement Win in Five...
📰
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of...
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
📰
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck...
📰
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck...
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris...
MassMutual Private Wealth & Trust FSB Has $40.54 Million Stock Holdings in Johnson & Johnson $JNJ
MassMutual Private Wealth & Trust FSB trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.0% during the...
MassMutual Private Wealth & Trust FSB Has $40.54 Million Stock Holdings in Johnson & Johnson $JNJ
MassMutual Private Wealth & Trust FSB trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.0% during the...
MassMutual Private Wealth & Trust FSB Acquires 665 Shares of Eli Lilly and Company $LLY
MassMutual Private Wealth & Trust FSB grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.6% during the 4th...
MassMutual Private Wealth & Trust FSB Acquires 665 Shares of Eli Lilly and Company $LLY
MassMutual Private Wealth & Trust FSB grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.6% during the 4th...
Pfizer Says Long-Awaited Lyme Vaccine Was Effective in Study
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study...
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Faraday Future Intelligent Electric Inc (NASDAQ:FFAI) gained 54.8% to $0.42 in pre-market trading after the company gained regulatory...
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Faraday Future Intelligent Electric Inc (NASDAQ:FFAI) gained 54.8% to $0.42 in pre-market trading after the company gained regulatory...
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Faraday Future Intelligent Electric Inc (NASDAQ:FFAI) gained 54.8% to $0.42 in pre-market trading after the company gained regulatory...
Nautical Ventures Adds AIATA Boat Brand to Its Product Portfolio
Brand Portfolio Expansion FORT LAUDERDALE, Fla., March 23, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ: VMAR) ("Vision Marine" or...
📰
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85%...
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN
Gradient Investments LLC lifted its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 1,098.9% in the 4th quarter, according to...
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN
Gradient Investments LLC lifted its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 1,098.9% in the 4th quarter, according to...